# US 2026/0097026 A1 · Inhibition of aortic valve calcification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097026 A1
- Document ID: US20260097026A1
- Status: Published application
- Kind: A1
- Application number: 19/115,899
- Filed: 2023-10-03
- Published: 2026-04-09
- Earliest claimed: 2022-10-04
- Inventors: Arsenii Zabirnyk; Ingvar Jarle Vaage; Kåre-Olav Stensløkken
- Web page: https://patentgrep.com/patent/US20260097026A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds useful for inhibiting calcification of aortic valves and to the treatment of diseases including aortic sclerosis and stenosis, and in particular to the use of the proton pump inhibitors including prazole compounds for the aforesaid treatments.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A method for the treatment, prevention, or inhibition of a disease associated with calcification of the aorta in a subject in need thereof comprising administering to the subject an effective amount of a prazole compound.

### Claim 26 (depends on 25)

Method of claim 25, wherein the prazole compound is a racemic mixture of S- and R-enantiomers of the prazole compound.

### Claim 27 (depends on 25)

Method of claim 25, wherein the prazole compound is an S-enantiomer.

### Claim 28 (depends on 25)

Method of claim 25, wherein the prazole compound is an R-enantiomer.

### Claim 29 (depends on 25)

Method of claim 25, wherein said prazole compound is selected from the group consisting of rabeprazole, omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole.

### Claim 30 (depends on 25)

Method of claim 25, wherein the prazole compound is a rabeprazole compound.

### Claim 31 (depends on 25)

Method of claim 25, wherein the prazole compound is a omeprazole compound.

### Claim at position 9

32-34. (canceled)

### Claim 35 (depends on 25)

Method of claim 25, wherein the disease associated with calcification of the aorta is aortic sclerosis.

### Claim 36 (depends on 25)

Method of claim 25, wherein the disease associated with calcification of the aorta is aortic stenosis.

### Claim 37 (depends on 25)

Method of claim 25, wherein the subject is at risk from developing a disease associated with calcification of the aorta.

### Claim 38 (depends on 25)

Method of claim 25, wherein the subject has asymptomatic changes in the aortic valve.

### Claim 39 (depends on 25)

Method of claim 25, wherein the subject has a biological valve prosthesis.

### Claim 40 (depends on 25)

Method of claim 25, wherein the subject has been diagnosed with rheumatic heart disease.

### Claim 41 (depends on 25)

Method of claim 25, wherein the subject has been diagnosed with peripheral vascular calcification.

### Claim 42 (depends on 25)

Method of claim 25, wherein the subject has congenital calcification.

### Claim 43 (depends on 25)

Method of claim 25, wherein the subject has been diagnosed with a pathological calcification disease in an area of the body other than the aorta.

### Claim 44 (depends on 25)

Method of claim 25, wherein administration of an effective amount of a prazole compound reduces the amount of calcification of the aorta of the subject.

### Claim 45

(canceled)

### Claim 46 (depends on 25)

Method of claim 25, wherein the rabeprazole compound is provided as a pharmaceutical composition comprising an effective amount of the rabeprazole compound and a pharmaceutically acceptable carrier or diluent.

### Claim 47 (depends on 25)

Method of claim 25, wherein the subject is at least 60 years of age.

### Claim 48 (depends on 25)

Method of claim 25, wherein the subject is at least 75 years of age.
